Baugh & Associates LLC Increases Position in Pfizer Inc. $PFE

Baugh & Associates LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 19.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 212,290 shares of the biopharmaceutical company’s stock after buying an additional 34,733 shares during the quarter. Pfizer comprises about 2.4% of Baugh & Associates LLC’s holdings, making the stock its 18th largest position. Baugh & Associates LLC’s holdings in Pfizer were worth $4,881,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. United Bank lifted its stake in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares during the period. Elevation Point Wealth Partners LLC lifted its stake in shares of Pfizer by 15.8% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 19,458 shares of the biopharmaceutical company’s stock worth $472,000 after acquiring an additional 2,649 shares during the period. Finally, Scotia Capital Inc. boosted its holdings in shares of Pfizer by 2.5% in the second quarter. Scotia Capital Inc. now owns 788,563 shares of the biopharmaceutical company’s stock valued at $19,113,000 after acquiring an additional 18,981 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Pfizer Stock Down 2.0%

PFE stock opened at $27.03 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average price is $26.84 and its 200 day moving average price is $25.69. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The company has a market cap of $153.70 billion, a P/E ratio of 19.88 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period last year, the company posted $0.63 earnings per share. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Morgan Stanley set a $27.00 price target on shares of Pfizer and gave the stock a “positive” rating in a report on Tuesday, March 17th. Bank of America lowered their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Citigroup started coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.